White Matter Hyperintensities are associated with Amyloid Burden in APOE4 Non-Carriers
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Previous preclinical studies have suggested a close relationship between cerebrovascular disease (CVD) and Alzheimer's disease. However, a direct correlation between CVD and amyloid burden has not yet been shown in humans. If there is a relationship between CVD and amyloid burden, it is possible that the apolipoprotein E4 (APOE4) genotype may have an effect on this relationship because APOE4 is a risk factor for the development of AD. We therefore evaluated the effects of APOE4 on the relationship between white matter hyperintensities (WMH), a marker of CVD, and amyloid burden, measured by 11 C-Pittsburgh compound B (PiB) PET. We recruited 53 patients with subcortical vascular cognitive impairments, who had both WMH on MRI and amyloid deposition assessed by PiB PET. Twenty-two of these patients were APOE4 carriers (41.5%). In the APOE4 non-carriers, a significant positive correlation was shown between the volume of WMH and PiB retention (β = 7.0 × 10 −3 , p = 0.034) while no significant correlation was found in APOE4 carriers (β = −9.0 × 10 −3 , p = 0.085). Statistical parametric mapping analyses in APOE4 non-carriers showed that WMH were associated with PiB retention in the bilateral medial occipitotemporal gyrus, cuneus, and superior cerebellum. Our results suggested that WMH are correlated with amyloid burden especially in the posterior brain regions in APOE4 non-carriers. However, this correlation was not observed in APOE4 carriers, perhaps because in these subjects the influence of APOE4 overrides the effect of CVD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders
Zlokovic, B. V. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3114 · Cited by 2,969
Mixed brain pathologies account for most dementia cases in community-dwelling older persons
Schneider, J. A., Arvanitakis, Z., Bang, W., & Bennett, D. A. (2007) · Neurology · doi:10.1212/01.wnl.0000271090.28148.24 · Cited by 1,992
RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain
Deane, R., Du Yan, S., Submamaryan, R. K., LaRue, B., Jovanovic, S., Hogg, E., Welch, D., Manness, L., Lin, C., Yu, J., et al. (2003) · Nature Medicine · doi:10.1038/nm890 · Cited by 1,611
Human ApoE isoforms differentially regulate brain amyloid-β peptide clearance
Castellano, J. M., Kim, J., Stewart, F. R., Jiang, H., DeMattos, R. B., Patterson, B. W., Fagan, A. M., Morris, J. C., Mawuenyega, K. G., Cruchaga, C., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002156 · Cited by 1,242 · cited 2×
“The APOE4 genotype is considered a major risk factor for AD and is thought to lower the age of onset for the development of AD and accelerate the aggregation of amyloid plaques [14].”
Self-citationAlzheimer’s disease is type 3 diabetes—Evidence reviewed
de la Monte, S. M., & Wands, J. R. (2008) · Journal of Diabetes Science and Technology · doi:10.1177/193229680800200619 · Cited by 1,158 · cited 1×
“However, since both AD and vascular pathologies usually occur in the elderly and share risk factors such as hypertension, diabetes, and hyperlipidemia, it is also possible that both pathologies can occur independently by chance [12, 29, 36].”
Clinical diagnosis of cerebral amyloid angiopathy: validation of the Boston criteria
Knudsen, K. A., Rosand, J., Karluk, D., & Greenberg, S. M. (2001) · Neurology · doi:10.1212/wnl.56.4.537 · Cited by 1,015
Holtzman, D. M., Bales, K. R., Tenkova, T., Fagan, A. M., Parsadanian, M., Sartorius, L. J., Mackey, B., Olney, J., McKeel, D., Wozniak, D., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.050004797 · Cited by 937 · cited 1×
“Although animal studies have shown that APOE4 is associated with enhanced amyloid-β aggregation [47, 48] and reduced amyloid clearance [14, 42, 49], resulting in amyloid-β deposition, the mechanism by which APOE4 promotes earlier age of amyloid deposition in humans is not known.”
apoE isoform–specific disruption of amyloid β peptide clearance from mouse brain
Deane, R., Sagare, A., Hamm, K., Parisi, M., Lane, S., Finn, M. B., Holtzman, D. M., & Zlokovic, B. V. (2008) · Journal of Clinical Investigation · doi:10.1172/jci36663 · Cited by 771 · cited 1×
“Although animal studies have shown that APOE4 is associated with enhanced amyloid-β aggregation [47, 48] and reduced amyloid clearance [14, 42, 49], resulting in amyloid-β deposition, the mechanism by which APOE4 promotes earlier age of amyloid deposition in humans is not known.”
Cerebral amyloid angiopathy in the elderly
Viswanathan, A., & Greenberg, S. M. (2011) · Annals of Neurology · doi:10.1002/ana.22516 · Cited by 643
Imaging of amyloid burden and distribution in cerebral amyloid angiopathy
Johnson, K. A., Gregas, M., Becker, J. A., Kinnecom, C., Salat, D. H., Moran, E. K., Smith, E. E., Rosand, J., Rentz, D. M., Klunk, W. E., et al. (2007) · Annals of Neurology · doi:10.1002/ana.21164 · Cited by 495
Cited by
White matter hyperintensities, cognitive impairment and dementia: an update
Prins, N. D., & Scheltens, P. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.10 · Cited by 1,284
Cardiovascular risk factors and future risk of Alzheimer’s disease
de Bruijn, R. F., & Ikram, M. A. (2014) · BMC Medicine · doi:10.1186/s12916-014-0130-5 · Cited by 322
Thal, D. R., Attems, J., & Ewers, M. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-141461 · Cited by 100
Vipin, A., Kumar, D., Soo, S. A., Zailan, F. Z., Leow, Y. J., Koh, C. L., Ng, A. S. L., Ng, K. P., & Kandiah, N. (2023) · Alzheimer's Research & Therapy · doi:10.1186/s13195-023-01251-4 · Cited by 17
Lee, W. J., Yoon, C. W., Kim, S.-W., Jeong, H. J., Seo, S., Na, D. L., Noh, Y., & Seong, J.-K. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.606600 · Cited by 12
Self-citation
Metadata
- Authors
- Noh, Y., Seo, S. W., Jeon, S., Lee, J. M., Kim, J.-H., Kim, G. H., Cho, H., Yoon, C. W., Kim, H. J., Ye, B. S., Kim, S. T., Choe, Y. S., Lee, K.-H., Kim, J. S., Ewers, M., Weiner, M. W., Lee, J.-H., Werring, D. J., Kang, D. R., Kim, C. S., & Na, D. L.
- Venue
- Journal of Alzheimer’s Disease
- Publisher
- SAGE Publications
- Published
- 2014-05-19
- Volume
- 40
- Issue
- 4
- Pages
- 877-886
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W1560162545
- Cited by
- 42
- References
- 19
- FWCI
- 3.14
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.